美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Xtrackers Nifty 500 India ETF

24.58

+0.04500.18%

成交量：131.00

成交额：3,217.81

市值：491.60万

市盈率：- -

高：24.58

开：24.58

低：24.58

收：24.54

52周最高：27.40

52周最低：23.33

股本：20.00万

流通股本：20.00万

量比：0.03

换手率：0.07%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

九源基因(02566)：JY54注射液IND申请获CDE正式受理

亚盛医药BTK降解剂APG-3288新药临床申请（IND）获CDE许可，全球临床开发再提速

友芝友生物-B(02496)：M 701取得FDA的IND批准

前沿生物：2025年末公司已就FB7013向国家药监局提交IND申请并获受理，FB7013正式进入临床申请审批通道

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IND"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.58,"timestamp":1770651660466,"preClose":24.535,"halted":0,"volume":131,"delay":0,"changeRate":0.0018341145302628145,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"交易中","change":0.045,"latestTime":"02-09 11:13:42 EST","open":24.58,"high":24.58,"low":24.58,"amount":3217.812867,"amplitude":0,"askPrice":24.65,"askSize":100,"bidPrice":24.47,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":24.535,"sharesOutstanding":200001,"nav":24.236,"aum":4847319.35,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.53,"preClose":24.535,"latestTime":"16:04 EST","volume":1,"amount":24.535,"timestamp":1770411858205,"change":-0.005,"changeRate":-0.000204,"amplitude":0},"volumeRatio":0.03301},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.03301,"shares":200001,"dividePrice":0,"high":24.58,"amplitude":0,"preClose":24.535,"low":24.58,"week52Low":23.3301,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":24.58,"eps":0,"divideRate":0,"volume":131,"delay":0,"ttmEps":0,"open":24.58,"prevYearClose":24.78,"prevWeekClose":24.535,"prevMonthClose":23.8555,"prevQuarterClose":24.78,"fiveDayClose":24.7868,"twentyDayClose":24.5796},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610600638","title":"九源基因(02566)：JY54注射液IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610600638?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司自主开发的化学1类创新药JY54 注射液新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外，在与已上市肥胖治疗药物的联合应用研究中，JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析，JY54注射液有望支持长效给药方案，并在体重管理领域展现差异化的临床应用潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","02566","BK4017","IND","LU1223082519.USD","LU1223083913.SGD","BK1161","CDE"],"gpt_icon":0},{"id":"2609095558","title":"亚盛医药BTK降解剂APG-3288新药临床申请（IND）获CDE许可，全球临床开发再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CDE","LU2125909916.SGD","LU1223083913.SGD","LU1923622291.USD","BK4017","LU1223082196.USD","AAPG","BK4144","LU1223082519.USD","APG","LU2125909759.SGD","TK","BK1161","06855","BK4139","IND","BK1574","BK4129"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496)：M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608824493?lang=zh_cn&edition=fundamental","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，于2026年1月31日，注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准，标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段，为全球患者带来新希望。M 701精准靶向Ep CAM和CD3，其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达，是关键治疗靶点;CD3可激活机体抗肿瘤免疫，二者协同实现精准治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02496"],"gpt_icon":0},{"id":"2606243834","title":"前沿生物：2025年末公司已就FB7013向国家药监局提交IND申请并获受理，FB7013正式进入临床申请审批通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2606243834","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606243834?lang=zh_cn&edition=fundamental","pubTime":"2026-01-26 20:05","pubTimestamp":1769429100,"startTime":"0","endTime":"0","summary":"关于BD合作事宜，公司始终秉持开放的态度，积极探索符合产品发展战略的合作机会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","BK0239","688221"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IND\",params:#limit:6,delay:false,,,undefined,":[]}}